We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

EUROMEDLAB 2022 Showcases Breakthrough Technologies and Cutting Edge Scientific Advances in Clinical Lab Diagnostics

By Carolyn Moody, RN - News Editor
Posted on 11 Apr 2022
Image: EUROMEDLAB 2022 was held 10th-14th April 2022 in Munich (Photo courtesy of IFCC)
Image: EUROMEDLAB 2022 was held 10th-14th April 2022 in Munich (Photo courtesy of IFCC)

The 24th European Congress of Clinical Chemistry and Laboratory Medicine (EUROMEDLAB 2022) saw exhibitors displaying innovations in clinical laboratory diagnostic technologies and offering attendees a hands-on experience with the latest instruments, machines and equipment. The five-day event held from 10th-14th April 2022 in Munich, Germany brought together scientists, laboratory specialists, clinicians, and industry participants in the field of clinical chemistry and laboratory medicine. The show attracted more than 3,000 active participants from across the world, and a number of international speakers and key opinion leaders were invited to address front-edge topics in diagnostic technologies, health care and scientific advances. Among the attendees were private and hospital laboratories, biologists, technicians, biomedical engineers and students.

Following its biannual pattern, EUROMEDLAB had originally been scheduled to take place in late November 2021. However, due to the critical pandemic situation at the venue – Munich in Bavaria, Germany – at that time, the congress was postponed to 10th-14th April 2022, prioritizing the health and safety of all visitors and exhibitors over other aspects. The congress was a hybrid event, with selected symposia and the opening and closing ceremony also held virtually. All COVID-19 restrictions to enter the Congress Centre had been cancelled, allowing all participants and visitors to freely access the Congress Centre and visit EUROMEDLAB. The importance of the live experience was reflected in the impressive reservation numbers. The floorspace of the 10,000-m2 Hall C1 and the ICM foyer was completely sold out and the number of research projects increased as compared to EUROMEDLAB 2020 with a total of 900 scientists submitting their abstracts as compared to 720 for the previous event. As such, the congress continued to grow in importance as a European hotspot for the science industry.

During the congress, attendees were able to experience the outstanding scientific program, which featured innovative and diverse educational opportunities that incorporated the best of clinical laboratory medicine and in vitro diagnostics, including lectures, symposia, recent advancements in clinical practice and science, poster presentations, and much more. A broad range of international speakers, key opinion leaders and stakeholders brought front-edge topics in health care, diagnostic technologies, scientific advances and professional matters to life. Special emphasis was placed on technological advancements, as the meeting aimed to connect the latest technological breakthroughs in diagnostic laboratory technology with the best minds in laboratory medicine to help attendees learn and implement the latest and greatest in clinical laboratory science, technology, and medicine. Attendees were also able to access a lively industry exhibition floor featuring the latest products and developments in diagnostic technologies brought by leading manufacturers. For those who were unable to able to attend the event in person, the show offered a brand-new format of interacting virtually with companies during the conference through the “Exhibition Floor Walks.”

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Neonatal Heel Incision Device
Tenderfoot

Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more